StarCaps marketer regroups
This article was originally published in The Tan Sheet
Executive Summary
In addition to voluntarily recalling its StarCaps weight-loss supplement, Balanced Health Products ceased working with the ingredient supplier and contract manufacturer linked to a batch tainted with the prescription diuretic bumetanide, says the firm's attorney, Marc Ullman. The response reflects the firm's accountability, and answers accusations that the adulteration is an indication that the regulation of dietary supplement products is lax, Ullman maintains. Representatives of National Football League players suspended when they tested positive for bumetanide blamed the loose regulation of the supplement industry for adulteration and, in turn, their positive tests (1"The Tan Sheet" Dec. 1, 2008, In Brief). Bumetanide is banned by the NFL because it may mask steroid use. Ullman said, "If it reflects on the industry, it is that the company performed the tests and started the recall." The New York City-based firm plans to reformulate the product but has not set a timetable for a re-launch, he says
You may also be interested in...
Diuretic found in StarCaps
Balanced Health Products voluntarily recalls one lot of the weight-loss supplement, which contained the undeclared diuretic bumetanide, FDA says Nov. 24. Bumetanide can cause serious loss of fluids and electrolytes and elevated uric acid concentrations. The New York City-based firm's president, Nikki Haskell, suspended shipment of StarCaps after National Football League players alleged the product was tainted after they were suspended for testing positive for bumetanide, which may mask steroid use (1"The Tan Sheet" Nov. 3, 2008, In Brief)
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.